This study is looking at whether bupropion hydrochloride, a medicine used for depression and to help stop smoking, can reduce fatigue (extreme tiredness) in people with end-stage kidney disease who are on hemodialysis. Fatigue is a very common and difficult symptom for these patients, and there isn't a specific treatment for it right now. You might be able to join if you are between 25 and 74 years old, have end-stage kidney disease, and have been on hemodialysis three times a week for at least three months. To be considered successful, the study hopes to see an improvement in your overall fatigue score after 8 weeks. This study is currently recruiting a small group of 16 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It is a small study, planning to enroll 16 participants.

What's involved

You will take bupropion hydrochloride orally three times a week during your regular dialysis sessions for 8 weeks. You will also complete questionnaires and have blood, and possibly urine and stool, collected at different times.

Compensation

Not stated in the trial record.

Follow-up

Your fatigue will be measured at the start of the study and again after 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.